摘要 |
This application relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and its use as an inhibitor of the NK-1 subtype of tachykinin receptors, as well as a process for its preparation and intermediates therefor. (I) wherein: D is a C<SUB>1</SUB>-C<SUB>3 </SUB>alkane-diyl; R<SUP>1 </SUP>is phenyl, which is optionally substituted with one to three substitutents independently selected from the group consisting of halo, C<SUB>1</SUB>-C<SUB>4 </SUB>alkyl, C<SUB>1</SUB>-C<SUB>4 </SUB>alkoxy, cyano, difluoromethyl, trifluoromethyl, and trifluoromethoxy; R<SUP>4 </SUP>is a radical selected from the group consisting of: (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH) |